Validea Joel Greenblatt Strategy Daily Upgrade Report - 6/27/2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 27 2025
0mins
Source: NASDAQ.COM
Nathan's Famous Inc. Stock Upgrade: Nathan's Famous Inc. received an upgrade in its rating from 80% to 90% based on Joel Greenblatt's Earnings Yield Investor model, indicating strong interest due to the company's solid fundamentals and stock valuation.
Company Overview: Nathan's Famous Inc. operates in the Restaurants industry, focusing on licensing and selling branded products like hot dogs, with a presence in approximately 79,000 locations across the United States.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NATH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NATH
About NATH
Nathan’s Famous, Inc. is a licensor, wholesaler and retailer of products marketed under its Nathan’s Famous brand, including its Nathan’s World Famous Beef Hot Dogs. The Company distributes its products in 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, Guam, and 20 foreign countries. The Branded Product Program segment is engaged in the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. The Product licensing segment includes royalties, from licensing a range of its branded products, including its hot dogs, sausage and corned beef products, frozen French fries and additional products, through retail grocery channels and club stores throughout the United States. The Restaurant operations segment is engaged in the sale of its products at Company-owned restaurants and earns fees and royalties from its franchised restaurants, including its virtual kitchens.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Nathan’s Famous, Inc. (NASDAQ: NATH) for potential violations related to its sale to Smithfield Foods, Inc. for $102.00 per share in cash, aiming to protect shareholder rights and seek increased compensation.
- Transaction Details: Penumbra, Inc. (NYSE: PEN) is being sold for $374.00 in cash or 3.8721 shares of Boston Scientific common stock, with Halper Sadeh LLC potentially advocating for more information and compensation to ensure transaction transparency for shareholders.
- Legal Rights: RAPT Therapeutics, Inc. (NASDAQ: RAPT) is selling to GSK plc for $58.00 per share, and Halper Sadeh LLC encourages shareholders to reach out to understand their legal rights and options, ensuring their interests are safeguarded in the transaction.
- Shareholder Support: Lisata Therapeutics, Inc. (NASDAQ: LSTA) is being sold for $4.00 per share in cash plus two non-tradeable rights, with Halper Sadeh LLC offering contingent fee legal services to help shareholders secure their rightful interests in the potential transaction.

Continue Reading
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde & Associates is investigating the acquisition of Penumbra, Inc. by Boston Scientific Corporation, where shareholders are expected to receive either $374 in cash or 3.8721 shares of Boston Scientific, highlighting a commitment to shareholder rights.
- RAPT Transaction Details: In the sale of RAPT Therapeutics, Inc. to GSK plc, shareholders are anticipated to receive $58 in cash per share, reflecting positive market expectations regarding the transaction's value.
- Nathan's Famous Acquisition: Nathan’s Famous, Inc. is set to receive $102 in cash per share from Smithfield Foods, indicating a direct financial benefit to shareholders from this acquisition.
- Lisata Transaction Terms: Lisata Therapeutics, Inc. shareholders will receive $4 in cash per share along with potential contingent value rights in the sale to Smithfield Foods, suggesting future revenue opportunities for investors.

Continue Reading





